MA56545A - Inhibiteurs allostériques d'egfr et leurs procédés d'utilisation - Google Patents
Inhibiteurs allostériques d'egfr et leurs procédés d'utilisationInfo
- Publication number
- MA56545A MA56545A MA056545A MA56545A MA56545A MA 56545 A MA56545 A MA 56545A MA 056545 A MA056545 A MA 056545A MA 56545 A MA56545 A MA 56545A MA 56545 A MA56545 A MA 56545A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- egfr inhibitors
- allosteric egfr
- allosteric
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864914P | 2019-06-21 | 2019-06-21 | |
| US201962877093P | 2019-07-22 | 2019-07-22 | |
| US202063027734P | 2020-05-20 | 2020-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56545A true MA56545A (fr) | 2022-04-27 |
Family
ID=74040509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056545A MA56545A (fr) | 2019-06-21 | 2020-06-19 | Inhibiteurs allostériques d'egfr et leurs procédés d'utilisation |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220233545A1 (fr) |
| EP (1) | EP3986407A4 (fr) |
| JP (1) | JP7601800B2 (fr) |
| KR (1) | KR20220052904A (fr) |
| CN (1) | CN114206342B (fr) |
| AU (1) | AU2020298298B2 (fr) |
| CA (1) | CA3144512A1 (fr) |
| MA (1) | MA56545A (fr) |
| WO (1) | WO2020257632A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020383423A1 (en) | 2019-11-11 | 2022-06-23 | Dana-Farber Cancer Institute, Inc. | Allosteric EGFR inhibitors and methods of use thereof |
| GB202106871D0 (en) * | 2021-05-13 | 2021-06-30 | Addex Pharmaceuticals Sa | Novel compounds |
| KR102733257B1 (ko) * | 2021-05-17 | 2024-11-26 | 에이치케이이노엔 주식회사 | 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| WO2023196409A1 (fr) * | 2022-04-05 | 2023-10-12 | Dana-Farber Cancer Institute, Inc. | Découverte d'un inhibiteur covalent de l'egfr par le biais de la cystéine 775 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2001875A2 (fr) * | 2006-03-08 | 2008-12-17 | Takeda San Diego, Inc. | Activateurs de la glucokinase |
| JP6845165B2 (ja) * | 2015-06-30 | 2021-03-17 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Egfr阻害剤およびその使用方法 |
| US10836733B2 (en) * | 2015-09-03 | 2020-11-17 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
| TW201834651A (zh) * | 2016-12-22 | 2018-10-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
| WO2018220149A1 (fr) * | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Composés |
| GB201710851D0 (en) * | 2017-07-06 | 2017-08-23 | Galápagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis |
-
2020
- 2020-06-19 MA MA056545A patent/MA56545A/fr unknown
- 2020-06-19 EP EP20826982.9A patent/EP3986407A4/fr active Pending
- 2020-06-19 KR KR1020227001839A patent/KR20220052904A/ko active Pending
- 2020-06-19 US US17/596,639 patent/US20220233545A1/en active Pending
- 2020-06-19 CN CN202080056893.5A patent/CN114206342B/zh active Active
- 2020-06-19 WO PCT/US2020/038705 patent/WO2020257632A1/fr not_active Ceased
- 2020-06-19 AU AU2020298298A patent/AU2020298298B2/en active Active
- 2020-06-19 JP JP2021576108A patent/JP7601800B2/ja active Active
- 2020-06-19 CA CA3144512A patent/CA3144512A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114206342B (zh) | 2024-10-22 |
| CA3144512A1 (fr) | 2020-12-24 |
| CN114206342A (zh) | 2022-03-18 |
| AU2020298298A1 (en) | 2022-02-03 |
| US20220233545A1 (en) | 2022-07-28 |
| JP2022537059A (ja) | 2022-08-23 |
| EP3986407A4 (fr) | 2023-07-19 |
| WO2020257632A1 (fr) | 2020-12-24 |
| AU2020298298B2 (en) | 2026-03-05 |
| KR20220052904A (ko) | 2022-04-28 |
| JP7601800B2 (ja) | 2024-12-17 |
| EP3986407A1 (fr) | 2022-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55136A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| EP3911648A4 (fr) | Inhibiteurs de pcsk9 et leurs procédés d'utilisation | |
| EP3968999A4 (fr) | Inhibiteurs de fgfr et leurs procédés d'utilisation | |
| MA54758A (fr) | Inhibiteurs de pcsk9 et leurs procédés d'utilisation | |
| MA54538A (fr) | Inhibiteurs d'apol1 et leurs procédés d'utilisation | |
| MA51848A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52765A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA55301A (fr) | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation | |
| MA52501A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52496A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| EP3962481A4 (fr) | Inhibiteurs de kcnt1 et procédés d'utilisation | |
| EP3962479A4 (fr) | Inhibiteurs de kcnt1 et procédés d'utilisation | |
| EP4037695A4 (fr) | Compositions oligonucléotidiques et leurs procédés d'utilisation | |
| EP3946329A4 (fr) | Agonistes bêta-adrénergique et leurs procédés d'utilisation | |
| EP3958872A4 (fr) | Compositions d'oligonucléotides et leurs procédés d'utilisation | |
| EP3846808A4 (fr) | Inhibiteurs de papd5 et leurs procédés d'utilisation | |
| MA51837A (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
| EP3810615A4 (fr) | Inhibiteurs d'arginase et procédés d'utilisation | |
| EP3765006A4 (fr) | Inhibiteurs d'arginase et procédés d'utilisation | |
| MA55025A (fr) | Anticorps anti-trem2 et leurs procédés d'utilisation | |
| EP3941475A4 (fr) | Pyridazinones et leurs procédés d'utilisation | |
| EP4284365A4 (fr) | Inhibiteurs de cdk2 et leurs procédés d'utilisation | |
| MA52797A (fr) | Inhibiteurs de masp -2 et procédés d'utilisation | |
| MA71645A (fr) | Pyridazinones et leurs procédés d'utilisation | |
| MA56545A (fr) | Inhibiteurs allostériques d'egfr et leurs procédés d'utilisation |